Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Drug Treatment Study for Children with Hemophilia A
Phase 3a open-label trial investigating the safety and efficacy of N8-GP (a recombinant, extended half-life factor VIII concentrate) for prophylaxis and treatment of bleeding episodes.
In order to participate you must meet the following criteria:
- Have hemophilia A.
- Are a male.
- Are 6 years of age or younger.
- Have never received any factor medications or blood products.
This is a partial list of elgibility requirements.